Compare Aventis Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs TORRENT PHARMA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA TORRENT PHARMA SANOFI INDIA/
TORRENT PHARMA
 
P/E (TTM) x 43.7 39.1 111.9% View Chart
P/BV x 8.0 8.5 94.5% View Chart
Dividend Yield % 1.1 0.7 151.5%  

Financials

 SANOFI INDIA   TORRENT PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
TORRENT PHARMA
Mar-19
SANOFI INDIA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs6,8401,964 348.3%   
Low Rs4,6301,245 371.9%   
Sales per share (Unadj.) Rs1,203.1453.4 265.3%  
Earnings per share (Unadj.) Rs165.325.8 641.0%  
Cash flow per share (Unadj.) Rs209.962.3 336.9%  
Dividends per share (Unadj.) Rs84.0017.00 494.1%  
Dividend yield (eoy) %1.51.1 138.2%  
Book value per share (Unadj.) Rs963.6279.2 345.2%  
Shares outstanding (eoy) m23.03169.22 13.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.83.5 134.7%   
Avg P/E ratio x34.762.2 55.8%  
P/CF ratio (eoy) x27.325.8 106.1%  
Price / Book Value ratio x6.05.7 103.6%  
Dividend payout %50.865.9 77.1%   
Avg Mkt Cap Rs m132,078271,513 48.6%   
No. of employees `0003.313.6 24.3%   
Total wages/salary Rs m4,06814,038 29.0%   
Avg. sales/employee Rs Th8,393.85,642.6 148.8%   
Avg. wages/employee Rs Th1,232.41,032.4 119.4%   
Avg. net profit/employee Rs Th1,153.0320.9 359.3%   
INCOME DATA
Net Sales Rs m27,70876,728 36.1%  
Other income Rs m897571 157.2%   
Total revenues Rs m28,60577,299 37.0%   
Gross profit Rs m6,23519,831 31.4%  
Depreciation Rs m1,0276,177 16.6%   
Interest Rs m75,038 0.1%   
Profit before tax Rs m6,0989,187 66.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m2,2921,254 182.8%   
Profit after tax Rs m3,8064,363 87.2%  
Gross profit margin %22.525.8 87.1%  
Effective tax rate %37.613.6 275.5%   
Net profit margin %13.75.7 241.6%  
BALANCE SHEET DATA
Current assets Rs m15,92250,375 31.6%   
Current liabilities Rs m6,23551,653 12.1%   
Net working cap to sales %35.0-1.7 -2,099.3%  
Current ratio x2.61.0 261.8%  
Inventory Days Days6492 69.1%  
Debtors Days Days2168 30.6%  
Net fixed assets Rs m7,53983,648 9.0%   
Share capital Rs m230846 27.2%   
"Free" reserves Rs m21,96246,397 47.3%   
Net worth Rs m22,19247,244 47.0%   
Long term debt Rs m039,129 0.0%   
Total assets Rs m29,839141,209 21.1%  
Interest coverage x872.12.8 30,886.9%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.90.5 170.9%   
Return on assets %12.86.7 192.0%  
Return on equity %17.29.2 185.7%  
Return on capital %27.512.3 223.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58722,103 34.3%   
Fx outflow Rs m7,1455,522 129.4%   
Net fx Rs m44216,581 2.7%   
CASH FLOW
From Operations Rs m3,73917,981 20.8%  
From Investments Rs m-731-2,413 30.3%  
From Financial Activity Rs m-1,972-13,145 15.0%  
Net Cashflow Rs m1,0362,380 43.5%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 7.0 205.1%  
FIIs % 14.6 12.6 115.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.8 119.3%  
Shareholders   15,184 26,511 57.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   PIRAMAL ENTERPRISES  GSK PHARMA  FRESENIUS KABI ONCO.  DR. REDDYS LAB  ABBOTT INDIA  

Compare SANOFI INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 224 Points Higher; Realty and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended on a positive note.

Related Views on News

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


May 29, 2020 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ORCHID PHARMA LTD COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS